H药 汉斯状®食管鳞状细胞癌获批上市 消化道肿瘤免疫治疗新选择

发布时间:2023-09-25 内容来源于: 浏览量:

内容来源:复宏汉霖


2023年9月22日,上海-复宏汉霖(2696.HK)宣布,公司自主研发的创新抗PD-1单抗H药——汉斯状®(通用名:斯鲁利单抗注射液)联合含氟尿嘧啶类和铂类药物用于PD-L1阳性的不可切除局部晚期/复发或转移性食管鳞状细胞癌(ESCC)的一线治疗新适应症的上市注册申请(NDA)获得国家药品监督管理局批准,为食管鳞癌患者提供了治疗新选择。此前,H药已获批治疗微卫星高度不稳定(MSI-H)实体瘤、鳞状非小细胞肺癌(sqNSCLC)和广泛期小细胞肺癌(ES-SCLC)三项适应症。复宏汉霖持续深化H药在肺癌、消化道肿瘤等领域的差异化、多维度布局,以期推动患者获得更高获益。




复宏汉霖董事长兼执行董事张文杰

H药获批第4项适应症用于治疗食管鳞癌,标志着这款高品质抗PD-1单抗为难治的消化道肿瘤领域带来新希望。自2022年3月获批上市以来,H药在临床实践中广泛惠及消化道肿瘤、肺癌等领域患者,树立起良好的口碑,并形成品牌效应。未来,我们将继续发挥H药优势和潜力,加快H药市场拓展步伐,为全球更多患者带去可负担的创新药物。


复宏汉霖执行董事、首席执行官、总裁兼首席财务官朱俊



以临床需求为导向,复宏汉霖深耕肿瘤免疫精准治疗领域,聚焦肿瘤重点病种,深化H药多瘤种布局,积极推进其在全球范围同步开展的多项免疫联合疗法试验。此次H药获批食管鳞癌,进一步验证了H药的治疗潜力,充分展现复宏汉霖的研发创新实力。期待H药未来更多积极临床结果的产出,进一步造福更广泛的癌症患者。


H药食管鳞癌Ⅲ期临床研究主要研究者、中国医学科学院肿瘤医院黄镜教授



食管鳞癌为食管癌中最为常见的病理类型,临床需求较大且总体预后相对较差。斯鲁利单抗围绕不能手术切除的局部晚期或转移性食管鳞癌开展了一项Ⅲ期临床研究(ASTRUM-007)并取得优异结果,该研究基于大样本量的本土人群数据,充分确证了斯鲁利单抗联合化疗一线治疗局部晚期/转移性、PD-L1阳性(PD-L1 CPS≥1)食管鳞癌患者,能够带来PFS、OS的显著获益,期待其在临床实践中惠及更多患者。

聚焦临床迫切需求,凝心打造优质选择

食管癌是全球第六大癌症死亡原因,也是我国的高发恶性肿瘤。统计显示,中国食管癌发病率和死亡率分别位列恶性肿瘤的第六和第四位,其中食管鳞癌为最常见的病理类型,约占中国所有食管癌病例的85.79%[1]。由于早期症状不明显,在我国约70%的患者确诊时已为局部晚期或转移性食管鳞癌,失去了手术治疗机会[2]。近年来,多项研究表明抗PD-1单抗联合化疗可为食管癌患者带来生存获益,免疫检查点抑制剂联合化疗已成为我国食管癌的一线治疗标准[3]


此次获批主要基于一项随机、双盲、多中心的Ⅲ期临床研究(ASTRUM-007),旨在研究斯鲁利单抗对比安慰剂联合化疗(顺铂+5-FU)在既往未接受治疗、PD-L1阳性(PD-L1 CPS≥1)的晚期食管鳞癌患者中的疗效和安全性。根据全球知名学术期刊Nature Medicine发表的ASTRUM-007临床研究结果显示,斯鲁利单抗联合化疗带来了总生存期(OS)和无进展生存期(PFS)的全面生存获益,并具备良好的安全性。值得注意的是,PD-L1高表达人群接受斯鲁利单抗联合化疗较意向性治疗(ITT)人群具有更大生存获益,在针对PD-L1 CPS≥10人群的分析中,斯鲁利单抗联合化疗组的中位OS长达18.6个月,较对照组绝对延长4.7个月,死亡风险降低41%。目前,ASTRUM-007研究成果已相继亮相于2022 ESMO Asia年会、2023 ASCO年会等国际学术会议,获得国际学术界高度认可。

多瘤种布局大癌种覆盖,致力惠及全球患者

围绕H药,公司聚焦肺癌与消化道肿瘤两大癌种,积极推进H药与公司其他产品的协同以及与创新疗法的联合,于全球同步开展10余项肿瘤免疫联合疗法临床试验,累计入组逾3600名受试者,国际化的临床研究数据有望为全球申报提供有力支撑。针对消化道肿瘤,H药已获批MSI-H实体瘤适应症,可为MSI-H高发的结直肠癌和胃癌等患者带去治疗希望。同时,该药在胃癌新辅助/辅助方面已进入Ⅲ期临床研究,有望使胃癌患者在前线便从肿瘤免疫疗法中获益。肺癌领域,H药已获批sqNSCLC和ES-SCLC两大适应症,并成为全球首个获批一线治疗小细胞肺癌(SCLC)的抗PD-1单抗,公司亦计划于2023年下半年就H药一线治疗非鳞状非小细胞肺癌(nsNSCLC)在中国递交上市申请。与此同时,H药治疗SCLC相继获得了美国食品药品监督管理局(FDA)和欧盟委员会(EC)授予的孤儿药资格认定,该药一线治疗ES-SCLC的欧盟上市许可申请(MAA)已于2023年3月获得欧洲药品管理局(EMA)受理,有望于2024年上半年获得批准。复宏汉霖亦在美国启动了一项H药对比一线标准治疗阿替利珠单抗用于ES-SCLC的头对头桥接试验,计划于2024年在美国递交上市许可申请(BLA)。此外,复宏汉霖还稳步推动H药局限期小细胞肺癌(LS-SCLC)的全球多中心Ⅲ期临床研究。


商业拓展方面,复宏汉霖针对H药进行了前瞻性的布局,并持续多维度、多渠道提升该产品的可及性,截至目前,H药已惠及逾3.7万名中国患者,并在中国境内完成29个省份的招标挂网,同时,已进入上海市、成都市、宁波市、厦门市、福建省、宁夏回族自治区等26个省/市级定制型商业补充医疗保险目录。针对海外市场,复宏汉霖与KGbio于2019年达成合作,授予其H药首个单药疗法及两项联合疗法在东南亚地区10个国家独家开发和商业化权益;2023年8月,公司进一步就H药在中东北非区域12个国家的独家商业化权益授予KGbio。此外,公司还授予复星医药H药在美国市场的独家商业化权益,协同拓展H药的海外市场布局,致力覆盖全球更广泛的患者群体。

未来,复宏汉霖将持续提升研产销全产链综合实力,深耕精准治疗与转化研究的治疗体系,多维度实现H药临床价值,持续打造肿瘤免疫治疗新标杆,为全球患者带去关爱与希望。

关于H药 汉斯状®

H药 汉斯状®为重组人源化抗PD-1单抗注射液(通用名:斯鲁利单抗注射液),是全球首个获批一线治疗小细胞肺癌的抗PD-1单抗,目前已有4项适应症获批上市,1项适应症上市申请在欧盟获受理,10余项临床试验同步在全球开展。


2022年3月,H药正式获批上市,目前可用于治疗微卫星高度不稳定(MSI-H)实体瘤、鳞状非小细胞肺癌(sqNSCLC)、广泛期小细胞肺癌(ES-SCLC)及食管鳞状细胞癌(ESCC)。H药联合化疗一线治疗广泛期小细胞肺癌(ES-SCLC)的上市申请也获得欧盟EMA受理。聚焦肺癌和消化道肿瘤,复宏汉霖积极推进H药与公司其他产品的协同以及与创新疗法的联合,相继获得中国、美国、欧盟等国家及地区的临床试验许可,在全球同步开展10余项肿瘤免疫联合疗法临床试验。截至目前,H药已于中国、美国、土耳其、波兰、格鲁吉亚等国家和地区累计入组超3600人,其中2项国际多中心临床试验入组白人的比例超过30%,是拥有国际临床数据较多的抗PD-1单抗之一。H药的3项关键性临床研究结果分别发表于知名期刊《美国医学会杂志》(JAMA)、《自然-医学》(Nature Medicine)和British Journal of Cancer。此外,H药还荣获《CSCO 小细胞肺癌诊疗指南》、《CSCO 非小细胞肺癌诊疗指南》、《CSCO 食管癌诊疗指南》、《CSCO 结直肠癌诊疗指南》、《CSCO 免疫检查点抑制剂临床应用指南》和《中国食管癌放射治疗指南》等多部权威指南推荐,为肿瘤临床诊疗提供重要参考。海外方面,H药治疗SCLC也已获得美国FDA和欧盟EC的孤儿药资格认定,并在美国启动了一项H药对比一线标准治疗阿替利珠单抗用于ES-SCLC的头对头桥接试验。

关于复宏汉霖

复宏汉霖(2696.HK)是一家国际化的创新生物制药公司,致力于为全球患者提供可负担的高品质生物药,产品覆盖肿瘤、自身免疫疾病、眼科疾病等领域,已在中国上市5款产品,在国际上市1款产品,19项适应症获批,2个上市申请分别获美国FDA和欧盟EMA受理。自2010年成立以来,复宏汉霖已建成一体化生物制药平台,高效及创新的自主核心能力贯穿研发、生产及商业运营全产业链。公司已建立完善高效的全球创新中心,按照国际药品生产质量管理规范(GMP)标准进行生产和质量管控,不断夯实一体化综合生产平台,其中,上海徐汇基地已获得中国和欧盟GMP认证,松江基地(一)也已获得中国GMP认证。


复宏汉霖前瞻性布局了一个多元化、高质量的产品管线,涵盖20多种创新单克隆抗体,并全面推进基于自有抗PD-1单抗H药 汉斯状®的肿瘤免疫联合疗法。继国内首个生物类似药汉利康®(利妥昔单抗)、中国首个自主研发的中欧双批单抗药物汉曲优®(曲妥珠单抗,欧洲商品名:Zercepac®,澳大利亚商品名:Tuzucip®和Trastucip®)、汉达远®(阿达木单抗)和汉贝泰®(贝伐珠单抗)相继获批上市,创新产品汉斯状®(斯鲁利单抗)已获批用于治疗微卫星高度不稳定(MSI-H)实体瘤、鳞状非小细胞肺癌、广泛期小细胞肺癌和食管鳞状细胞癌,并成为全球首个获批一线治疗小细胞肺癌的抗PD-1单抗。公司亦同步就16个产品在全球范围内开展30多项临床试验,对外授权全面覆盖欧美主流生物药市场和众多新兴市场。


Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ESCC

Shanghai, China, Sep?22nd, 2023 – Shanghai Henlius Biotech, Inc. (2696. HK) announced that?the new drug application (NDA) for new indication of HANSIZHUANG (serplulimab injection), an innovative anti-PD-1 monoclonal antibody independently developed by the company, in combination with drugs containing fluorouracil and platinum for the first-line treatment of patients with PD-L1 positive unresectable locally advanced/recurrent or metastatic esophageal squamous cell carcinoma (ESCC), has been approved by the National Medical Products Administration (the "NMPA"),?providing a new treatment option for patients with ESCC. Up to date, HANSIZHUANG has been approved for the treatment of microsatellite instability-high (MSI-H) solid tumors, squamous non-small cell lung cancer (sqNSCLC), and extensive stage small cell lung cancer (ES-SCLC). To further benefit patients, Henlius continues to differentiate and optimize product portfolios and the roadmap of HANSIZHUANG in lung cancer, gastrointestinal cancer, and other cancers.


Wenjie Zhang, Chairman, and Executive Director of Henlius, remarked,?"ESCC is the fourth approved indication of HANSIZHUANG and its approval signifies that this high-quality anti-PD-1 mAb?offers a new ray of hope for the treatment of difficult-to-treat gastrointestinal cancer. Since it launched in March 2022, HANSIZHUANG has benefited a wide range of patients with lung cancer, gastrointestinal cancer, and other tumors, further solidifying its positive reputation with a strong brand effect. Moving forward, we will continue leveraging the strengths of HANSIZHUANG and fully tapping its potential to accelerate market expansion to provide affordable, innovative treatments to more patients worldwide."


Jason Zhu, Executive Director, Chief Executive Officer, President and Chief Financial Officer of Henlius, said, "Henlius is driven by unmet clinical needs and has devoted itself to precision immunotherapy for tumors. We are focusing on major cancer types, steadily expanding the clinical layout of HANSIZHUANG in multiple cancer types, and actively initiating immune combination therapy trials worldwide. The approval of ESCC further validates the potential of HANSIZHUANG and demonstrates the innovation capabilities of Henlius. We look forward to more positive study results of HANSIZHUANG to make further contributions to cancer treatment for more cancer patients."


Prof. Jing Huang, the leading principal investigator?of?ASTRUM-007,?from Cancer Hospital Chinese Academy of Medical Sciences,?said, "ESCC is the most common pathological type of esophageal cancer with high clinical demand and relatively poor overall prognosis. The phase 3 clinical study (ASTRUM-007) on serplulimab plus chemotherapy for?unresectable?locally advanced/metastatic esophageal cancer achieved promising results, which was conducted on a large sample of the local population and fully demonstrated that serplulimab in combination with chemotherapy as a first-line treatment for locally advanced/metastatic and PD-L1 positive (PD-L1 CPS≥1)?esophageal cancer patients can significantly improve progression-free survival (PFS) and overall survival (OS). We are hoping that serplulimab will benefit more patients in clinical practice."

Providing a new solution for urgent clinical needs

Esophageal cancer is the sixth leading cause of cancer-related deaths worldwide as well as a prevalent malignant tumor in China. According to the data, the incidence and mortality of esophageal cancer rank sixth and fourth, respectively, among all malignant tumors in China, of which ESCC is the most common pathological type that accounts for about 85.79% of all esophageal cancer cases[1].?As the symptoms of early esophageal cancer are often subtle, about 70% of patients are diagnosed at mid-to-late stage, missing out on surgical treatment[2]. In recent years, many studies have shown that anti-PD-1 mAb combined with chemotherapy can bring survival benefits to patients with esophageal cancer. Up to date, immune checkpoint inhibitor combined with chemotherapy has become the standard first-line treatment for advanced esophageal cancer in China[3].


The approval was primarily based on ASTRUM-007, a randomized, double-blind, multicenter, phase 3 study aiming to compare the efficacy and safety of serplulimab versus placebo in combination with chemotherapy (5-FU + cisplatin) in patients with previously untreated, PD-L1–positive (PD-L1 CPS≥1), advanced ESCC. According to the study results published in the international leading journal?Nature Medicine,?serplulimab in combination with chemotherapy significantly improved progression-free survival (PFS) and overall survival (OS), its safety was also manageable. Notably, the PD-L1 high-expression group receiving serplulimab combined with chemotherapy gained a greater survival benefit comparing to the intention-to-treat (ITT) group,?in the analysis?of the group with?PD-L1 CPS≥10,?the combination?of?serplulimab and?chemotherapy group had a median OS of 18.6?months,?with an absolute extension of 4.7 months compared to the control group and a?41% reduction?in the risk of?death.?The results of ASTRUM-007 have been released at many world-class conferences, such as the 2022 ESMO Asia Congress and the 2023 ASCO Annual Meeting,?receiving high recognition from the international academic community.

Widening indication coverage for patients worldwide

Henlius focuses on lung and gastrointestinal cancer and promotes the synergy of HANSIZHUANG with innovative therapies, in which more than 10 clinical trials on immuno-oncology combination therapies have been initiated worldwide. As of now, the company has enrolled more than 3,600 subjects, and the global clinical research data will provide strong support for its NDAs in overseas markets.?In terms of gastrointestinal cancer, HANSIZHUANG has been approved for the treatment of MSI-H solid tumours, which brings hope to patients with MSI-H colorectal cancer and MSI-H gastric cancer.?Furthermore, HANSIZHUANG has led the way with a phase 3 clinical study on neoadjuvant/adjuvant therapies for gastric cancer, striving to benefit gastric cancer patients from the early line of immunotherapy. In the field of lung cancer, HANSIZHUANG has been approved for sqNSCLC and ES-SCLC, making it the world's first anti-PD-1 mAb for the first-line treatment of SCLC. The company also plans to submit a marketing application for HANSIZHUANG as a first-line treatment for non-squamous non-small cell lung cancer (nsNSCLC) in China in the second half of 2023. In addition, HANSIZHUANG was also granted orphan drug designations by the U.S. Food and Drug Administration (FDA) and European Commission (EC)?for the treatment of SCLC, and its Marketing Authorization Application (MAA) for the first-line treatment of ES-SCLC was validated by the European Medicines Agency (EMA) in March 2023, with the expectation of approval in the first half of 2024. Henlius also lanuched a head-to-head bridging trial of HANSIZHUANG versus first-line standard-of-care atezolizumab for ES-SCLC in the U.S. and?the company plans to submit a Biologics License Application (BLA) for HANSIZHUANG in the U.S. in 2024.?Furthermore, Henlius is steadily advancing a global multi-center clinical research of HANSIZHUANG for the limited stage small cell lung cancer (LS-SCLC).


Henlius proactively promotes the commercialization of HANSIZHUANG to enhance its accessibility through multiple dimensions and channels. Up to date, HANSIZHUANG has benefited over 37,000 Chinese patients and has completed the tendering process on the procurement platform in 29 provinces in Chinese mainland and was included into the customized commercial medical insurance directory in 26?Provinces and cities such as Shanghai, Chengdu, Ningbo, Xiamen, Fujian, Ningxia Hui Autonomous Region, etc. For the overseas market, Henlius forged a partnership with Kalbe Genexine Biologics (KGbio) to grant it an exclusive license to develop and commercialize HANSIZHUANG in relation to its first?monotherapy and two combination therapies in 10 Southeast Asian countries. In August 2023, the company further granted KGbio exclusive development and commercialization authorizations of HANSIZHUANG in 12 Middle East and North Africa (MENA) countries. In addition, Henlius entered into an exclusive license agreement with Fosun Pharma for the commercialization of HANSIZHUANG in the U.S., aiming to expand the overseas market layout of HANSIZHUANG and reach out to a wider range of global patients.


In the future, Henlius will continue to enhance its capabilities in innovation, manufacturing, and commercialization, dedicating its efforts to the development of a system for?precision treatment and translational medicine research and maximizing the clinical value of HANSIZHUANG to set the pace in tumor immunotherapy to deliver warmth and hope to patients all over the globe.

【参考文献】

[1]?Chen R, Zheng R, Zhang S, et al. Patterns and trends in esophageal cancer incidence and mortality in China: an analysis based on cancer registry data[J]. Journal of the National Cancer Center, 2023.

[2]?王天云, 张瑜, 徐泳, 卢铀, & 彭枫. (2018). 晚期食管鳞癌患者三线化疗疗效及生存分析. 四川省抗癌协会老年肿瘤治疗专委会第三次学术年会暨四川省抗癌协会抗癌药物专业委员会第一次学术年会. 四川省抗癌协会.

[3] 食管癌诊疗指南(2022年版). 中国国家卫生健康委员会.

About HANSIZHUANG

HANSIZHUANG (recombinant humanized anti-PD-1 monoclonal antibody injection, generic name: serplulimab injection) is the first anti-PD-1 mAb for the first-line treatment of SCLC. Up to date, 4 indications are approved for marketing in China, 1 marketing application is?under review in the EU, and more than 10 clinical trials are ongoing across the world.


HANSIZHUANG was launched in March 2022 and has been approved by the NMPA for the treatment of MSI-H solid tumours, squamous non-small cell lung cancer (sqNSCLC), extensive-stage small cell lung cancer (ES-SCLC), and esophageal squamous cell carcinoma (ESCC). Its marketing applications of the first-line treatment for ES-SCLC are under review by the EMA. Focusing on lung and gastrointestinal cancer, the synergy of HANSIZHUANG with in-house products of the company and innovative therapies are being actively promoted. It has successively obtained clinical trial approvals in China, the U.S., the EU and other countries and regions to initiate more than 10 clinical trials on immuno-oncology combination therapies in a wide variety of indications. As of now, the company has enrolled more than 3,600 subjects in China, the U.S., Turkey, Poland, Georgia and other countries and regions, and the proportion of White is over 30% in two MRCTs, making HANSIZHUANG an anti-PD-1 mAb with one of the largest global clinical data pools. The results of 3 pivotal trials of HANSIZHUANG were published in the?Journal of the American Medical Association?(JAMA),?Nature Medicine?and the?British Journal of Cancer, respectively. Furthermore, HASIZHUANG was recommended by the?CSCO Guidelines for Small Cell Lung Cancer, the?CSCO Guidelines for Non-Small Cell Lung Cancer, the?CSCO Guidelines for Esophageal Cancer,?the?CSCO Guidelines for Colorectal Cancer,?the?CSCO Clinical Practice Guidelines on Immune Checkpoint Inhibitor,?the?China Guidelines for Radiotherapy of Esophageal Cancer,?and other definitive guides, providing valuable references for clinical diagnosis and treatment of?tumours. On the other hand, serplulimab was granted orphan drug designations by the U.S. FDA and the EC for the treatment of SCLC, and its bridging head-to-head trial in the United States to compare HANSIZHUANG to standard of care atezolizumab (anti-PD-L1 mAb) for the first-line treatment of ES-SCLC is well under way.


About Henlius

Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable, and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases, and ophthalmic diseases. Up to date, 5 products have been launched in China, 1 has been approved for marketing in overseas markets, 19 indications are approved worldwide, and 2 marketing applications have been accepted for review in the U.S., and the EU, respectively. Since its inception in 2010, Henlius has built an integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product life cycle including R&D, manufacturing and commercialization. It has established global innovation centers and Shanghai-based manufacturing facilities in line with global Good Manufacturing Practice (GMP), including Xuhui Plant certificated by China and the EU GMP and Songjiang First Plant certificated by China GMP.


Henlius has pro-actively built a diversified and high-quality product pipeline covering over 20 innovative monoclonal antibodies (mAbs) and has continued to explore immuno-oncology combination therapies with proprietary HANSIZHUANG (anti-PD-1 mAb) as backbone. Apart from the launched products HANLIKANG (rituximab), the first China-developed biosimilar, HANQUYOU (trastuzumab for injection, trade name in Europe: Zercepac®; trade names in Australia: Tuzucip®?and Trastucip®), the first China-developed mAb biosimilar approved both in China and Europe, HANDAYUAN (adalimumab) and HANBEITAI (bevacizumab), the innovative product HANSIZHUANG has been approved by the NMPA for the treatment of MSI-H solid tumors, squamous non-small cell lung cancer (sqNSCLC) and extensive-stage small cell lung cancer (ES-SCLC), and esophageal squamous cell carcinoma (ESCC), making it the world's first anti-PD-1 mAb for the first-line treatment of SCLC. What's more, Henlius has conducted over 30 clinical studies for 16 products, expanding its presence in major markets as well as emerging markets.




分享
x

抖音二维码

扫一扫

XML 地图 | Sitemap 地图

威尼斯登录中心